Citigroup Has Lowered Expectations for Ralliant (NYSE:RAL) Stock Price

Ralliant (NYSE:RAL) had its price target cut by equities research analysts at Citigroup from $61.00 to $51.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price objective would suggest a potential upside of 29.03% from the stock’s previous close.

A number of other analysts also recently commented on RAL. Morgan Stanley reiterated an “overweight” rating and issued a $45.00 price objective on shares of Ralliant in a report on Friday. Barclays increased their price target on Ralliant from $59.00 to $60.00 and gave the company an “overweight” rating in a report on Wednesday, January 7th. Royal Bank Of Canada lowered their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday. Vertical Research raised Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Friday. Finally, Oppenheimer dropped their price objective on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Friday. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $51.30.

Ralliant Price Performance

NYSE RAL traded up $1.14 during mid-day trading on Friday, hitting $39.53. The stock had a trading volume of 2,916,384 shares, compared to its average volume of 1,792,062. The firm’s 50 day moving average is $51.72 and its 200 day moving average is $46.77. Ralliant has a twelve month low of $37.27 and a twelve month high of $57.02. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.49 and a quick ratio of 1.03. The stock has a market capitalization of $4.46 billion and a price-to-earnings ratio of 31.13.

Ralliant (NYSE:RAL) last announced its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.02. The business had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The firm’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Hedge Funds Weigh In On Ralliant

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Ralliant by 10.7% in the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock valued at $637,995,000 after acquiring an additional 1,415,327 shares in the last quarter. Dodge & Cox purchased a new stake in shares of Ralliant in the 2nd quarter valued at approximately $523,571,000. Viking Global Investors LP acquired a new stake in shares of Ralliant in the 2nd quarter valued at $257,200,000. State Street Corp acquired a new stake in shares of Ralliant in the 2nd quarter valued at $213,096,000. Finally, Flossbach Von Storch SE increased its holdings in Ralliant by 1.7% in the third quarter. Flossbach Von Storch SE now owns 4,152,866 shares of the company’s stock valued at $181,605,000 after buying an additional 67,963 shares during the last quarter.

Ralliant News Roundup

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target—a bullish analyst signal that can attract buying interest. RAL: Vertical Research upgrade
• Positive Sentiment: Ralliant earned a relative strength rating upgrade and hit a key technical benchmark, which can support short‑term momentum and algorithmic buying. Ralliant earns relative strength rating upgrade
• Neutral Sentiment: The company reported Q4 2025 results that slightly beat consensus on EPS ($0.69 vs. $0.67) and revenue ($554.6M vs. ~$543M), showing modest underlying revenue growth. These beats are offset by other items below. Ralliant Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Ralliant took a $1.4 billion non‑cash goodwill impairment in its Test & Measurement segment (primarily tied to the EA Elektro‑Automatik acquisition), producing a reported net loss of ~$1.4B and triggering a sharp selloff. This is the primary negative catalyst weighing on the stock. Ralliant Plunges on $1.4B Electric Vehicle Impairment Charge
• Negative Sentiment: Following the impairment and the big loss, multiple law firms have launched investigations into whether Ralliant and its officers complied with securities laws (Johnson Fistel, Holzer & Holzer, Block & Leviton), increasing legal uncertainty and potential headline risk. Johnson Fistel investigation notice Holzer & Holzer investor alert
• Negative Sentiment: Shares recently hit an all‑time low as investors reacted to the magnitude of the impairment and the company’s prior swing to large losses, underscoring elevated downside sensitivity to further negative news. Ralliant drops to all-time low

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.